Sheffield MND Care and Research Centre

Sheffield Institute for Translational Neuroscience (SITraN)

The Sheffield Motor Neuron Disorders Care and Research Centre offers multi-disciplinary care and support to patients and carers living with MND and other neurodegenerative conditions. As part of SITraN and NIHR Sheffield Biomedical Research Centre we offer the broadest range of clinical trials available to MND patients in the UK.

sitran
University of Sheffield

The Sheffield MND Care Centre receives >1200 patient visits annually including 120 new referrals. We offer multi-disciplinary care and support to patients and carers living with Motor Neuron Disorders (MND) from across the South Yorkshire region and the whole of the UK.

Sheffield is a major site for clinical trials of neuroprotective therapies, including genetic therapies and studies to improve symptom management and quality of life for people living with MND. As part of the Sheffield Institute for Translational Neuroscience (SITraN) we are positioned to take preclinical laboratory findings and translational interventions forward into clinical evaluation for patient benefit. SITraN has >220 researchers working on disease biology, genetic subclassification and drug discovery for neurodegenerative diseases.

The Queen’s Anniversary Prize for Higher Education 2019 was awarded to the University of Sheffield for improving outcomes for neurodegenerative diseases, highlighting the HeadUp collar for neck weakness, genetic therapy research and progress in biomarkers for MND trials emerging from our programmes.

Contact
Location
385 Glossop Road, Sheffield, S10 2HQ, UK
Contact
T:+44 114 2222231 or +44 114 2222295
E:pamela.shaw@sheffield.ac.uk
Contact by email

Our Specialists

Pamela Shaw

Professor of Neurology

Professor Dame Pam Shaw is Professor of Neurology at the University of […]

Pamela Shaw
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Completed
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Completed
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more